The Clinical Scholars Biomedical Research Training Program at Memorial Sloan-Kettering Cancer Center (MSKCC) provides a mentored laboratory training experience in cancer research for outstanding MD's or MD/PhD's led by Dr. David Spriggs. The goal of the Program is to prepare highly qualified physician-scientists for a career at the interface of cancer biology and clinical research. The fellows are trained by principal investigators with an exceptionally broad range of scientific interests spanning most areas of modern cancer research. More than one half of the 44 preceptors are physician scientists, who represent strong role models for careers combining laboratory and clinical research and practice. The Program consists of a structured and cohesive two-year curriculum that combines laboratory research, didactic course work in cancer biology, bioinformatics training and career development workshops. Trainees have access to all resources of the Memorial Sloan-Kettering Cancer Center, an instituion in which basic, translational and clinical research activites take place in close proximity in a highly collaborative research environment. The research areas of principal emphasis include: 1) Human cancer biology, mouse models of cancer, genetics and molecular pathology; 2) Drug development and mechanism-based therapeutics; 3) Signals and pathways involved in control of cell proliferation; 4) Regulatory pathways involved in developmental biology and cell differentiation; 5) Cell-cell interactions, adhesion and protein targeting; 6) Tumor immunology, immunotherapy and transplantation biology. The Clinical Scholars Biomedical Research Training Program has had a long and successful training history with nearly all of its graduates continuing in highly productive research careers. Thus, the Program has had signficant impact in meeting the national need for physician-scientists who can play leading roles in translating basic discoveries in cancer biology into patient care.

Public Health Relevance

Because they function at the interface between the laboratory and the clinic, physician-scientists play a critical role in the translation of scientific discoveries into new diagnostics and therapeutics. This training program is designed to prepare board eligible/qualified physicians to carry out independent laboratory based translational research. These individuals will increase our understanding the origins of cancer and lead the development of new cancer treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Lim, Susan E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Sharma, Sai Kiran; Chow, Andrew; Monette, Sebastien et al. (2018) Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. Cancer Res 78:1820-1832
Untch, Brian R; Dos Anjos, Vanessa; Garcia-Rendueles, Maria E R et al. (2018) Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers. Cancer Res 78:4642-4657
Maus, Marcela V; Plotkin, Jason; Jakka, Gopinadh et al. (2016) An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity. Mol Ther Oncolytics 3:1-9
Viny, Aaron D; Ott, Christopher J; Spitzer, Barbara et al. (2015) Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. J Exp Med 212:1819-32
Callahan, Margaret K; Masters, Gregg; Pratilas, Christine A et al. (2014) Paradoxical activation of T cells via augmented ERK signaling mediated by a RAF inhibitor. Cancer Immunol Res 2:70-9
Snyder, Alexandra; Makarov, Vladimir; Merghoub, Taha et al. (2014) Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 371:2189-2199
Diab, Adi; Jenq, Robert R; Rizzuto, Gabrielle A et al. (2013) Enhanced responses to tumor immunization following total body irradiation are time-dependent. PLoS One 8:e82496
Rizzuto, Gabrielle A; Merghoub, Taha; Hirschhorn-Cymerman, Daniel et al. (2009) Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. J Exp Med 206:849-66
Marcucci, Guido; Maharry, Kati; Radmacher, Michael D et al. (2008) Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 26:5078-87
Perales, M-A; Ishill, N; Lomazow, W A et al. (2007) Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease. Bone Marrow Transplant 40:481-6

Showing the most recent 10 out of 115 publications